Revenue - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended						9 Months Ended		12 Months Ended
	May 31, 2023	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2022
Disaggregation Of Revenue [Line Items]
Upfront cash payment	$ 75,000,000
Revenue						$ 15,202,000	$ 10,012,000	$ 31,990,000	$ 30,871,000
Accounts and other receivables, net						483,000		483,000				$ 15,503,000
Current liabilities						63,896,000		63,896,000				34,537,000
Accrued expenses						13,417,000		13,417,000				16,359,000
Accounts payable						9,580,000		$ 9,580,000				5,919,000
Scenario, Forecast [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment											$ 7,500,000
Alimera Sciences, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Product rights agreement, closing date								May 17, 2023
Receipt of upfront license fee								$ 75,000,000
RPA [Member] | SWK [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment								16,500,000
Revenue						249,000,000	240,000,000	737,000,000	663,000,000
Deferred revenue, current						1,300,000		1,300,000				1,200,000
Deferred revenue, non-current						12,700,000		12,700,000				$ 13,600,000
YUTIQ [Member]
Disaggregation Of Revenue [Line Items]
Revenue							7,300,000		19,300,000
DEXYCU [Member]
Disaggregation Of Revenue [Line Items]
Revenue							2,400,000		10,700,000
Product [Member]
Disaggregation Of Revenue [Line Items]
Revenue						816,000	9,720,000	13,483,000	30,048,000
Product [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue						0	20,000	471,000,000	87,000
Product [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue						1,000,000		1,200,000
License and Collaboration Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue						14,137,000	52,000	17,768,000	160,000
License and Collaboration Agreement [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue						17,000,000	50,000	65,000,000	158,000
License and Collaboration Agreement [Member] | Alimera Sciences, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Revenue						394,000,000		799,000,000
License and Collaboration Agreement [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue						13,600,000		16,800,000
Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Revenue						249,000	240,000	739,000	663,000
Royalty Income [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue						0	0	0	0
Product Sales, License and Collaboration Revenue, or Royalty Income [Member] | Exclusive License Agreement with Betta Pharmaceuticals, Co., Ltd.
Disaggregation Of Revenue [Line Items]
Revenue						0	$ 0	0	$ 0
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment								75,000,000
Deferred revenue, current						38,500,000		38,500,000
Deferred revenue, non-current						19,600,000		19,600,000
Carrying value of internally developed intangible assets						$ 0		$ 0
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Scenario, Forecast [Member]
Disaggregation Of Revenue [Line Items]
Guaranteed payments		$ 1,875,000	$ 1,875,000	$ 1,875,000	$ 1,875,000						$ 7,500,000
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Maximum [Member]
Disaggregation Of Revenue [Line Items]
Royalties payment period								2028
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Maximum [Member] | Scenario, Forecast [Member]
Disaggregation Of Revenue [Line Items]
Royalty payments										$ 70,000,000
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Minimum [Member]
Disaggregation Of Revenue [Line Items]
Royalties payment period								2025
Supply Agreement [Member] | Alimera Sciences, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Initial term of the supply agreement								2 years
Renewal term of supply agreement								1 year
Initial Term of Estimated Supply Units								2 years